摘要
目的探讨骨显像与几种常用肿瘤标记物检测在评价89SrCl2治疗肺癌晚期骨转移疗效方面的价值。方法 93例肺癌晚期骨转移患者在89 SrCl2治疗前、后分别行骨显像检查及肿瘤标记物(CYFRA21-1、NSE和CEA)检测,并进行评价。结果在治疗后1 w、2 w、1个月和3个月,患者疼痛评分较治疗前明显下降(P<0.001);骨显像示部分患者治疗后病灶缩小,甚至消失,有效率为70.97%;治疗前、后血清CYFRA21-1、CEA和NSE水平比较,差异无统计学意义(P>0.05)。治疗后未出现严重毒副反应。结论骨显像可显示晚期肺癌骨转移在89SrCl2治疗前、后病灶数目及大小变化;肿瘤标记物(CYFRA21-1、NSE和CEA)检测对评价89SrCl2治疗肺癌晚期骨转移患者的疗效无明显意义。
Objective To explore the value of bone imaging and detection of the common tumor markers including CYFRA21-1,NSE and CEA in the therapeutic efficacy evaluation of 89SrCl2 on the bone metastases with advanced lung cancer.Methods The bone imaging and detected tumor markers including CYFRA21-1,NSE and CEA were evaluated after 93 cases of bone metastases with advanced lung cancer were treated with 89SrCl2.Results There were significant differences in the pain score and the remission pain rate during the first week,the second week,the first month and the third month respectively（P〈0.001）.The bone imaging showed that some patients′tumor reduced and even disappeared,and the efficiency rate was 70.97%.There were no significant differences in the tumor markers including CYFRA21-1,NSE and CEA between before and after the treatment and no serious adverse effects after the treatment.Conclusion The bone imaging can show the nidus changes in numbers and sizes before and after the bone metastases with advanced lung cancer are treated with 89SrCl2 on and the tumor markers including CYFRA21-1,NSE and CEA have no significance in evaluating the therapeutic efficacy of 89SrCl2 on bone metastases with advanced lung cancer.
出处
《成都医学院学报》
CAS
2016年第2期194-197,共4页
Journal of Chengdu Medical College
